September 2025
1. KEREMITCI D, Tuna O, Houdjedj A, Kazan H, et al
   Transcriptional states of lung cancer microenvironment reveal macrophage subtype dynamics linked to disease progression.
   J Immunol. 2025 Sep 16:vkaf253. doi: 10.1093.
   

   >> Share

   
   
2. WANG S, Li F, Zhang L, Ping Y, et al
   HMGB1 inhibits the IFN-gamma-induced PD-L1 expression in NSCLC.
   J Immunol. 2025;214:2480-2488.
   

   >> Share

   
   March 2025
3. SNYDER M, Wang Z, Lara B, Fimbres J, et al
   The aryl hydrocarbon receptor controls IFN-gamma-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma.
   J Immunol. 2025;214:413-432.
   

   >> Share

   
   November 2024
4. MA B, Kamle S, Sadanaga T, Lee CM, et al
   Chitinase 3-like-1 Inhibits Innate Antitumor and Tissue Remodeling Immune Responses by Regulating CD47-SIRPalpha- and CD24-Siglec10-Mediated Phagocytosis.
   J Immunol. 2024;213:1279-1291.
   

   >> Share

   
   October 2024
5. OZAKINCI H, Song X, Nazario GS, Lila T, et al
   Rapid Autopsy to Define Dendritic Cell Spatial Distribution and T Cell Association in Lung Adenocarcinoma.
   J Immunol. 2024;213:1033-1041.
   

   >> Share

   
   September 2024
6. DIAMANTOPOULOS N, Li J, Bouchard A, Joumier L, et al
   ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations.
   J Immunol. 2024;213:753-762.
   

   >> Share

   
   July 2024
7. SHANAHAN SL, Kunder N, Inaku C, Hagan NB, et al
   Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer.
   J Immunol. 2024 Jul 31:ji2400268. doi: 10.4049/jimmunol.2400268.
   

   >> Share

   
   May 2024
8. SAXENA R, Bushey RT, Campa MJ, Gottlin EB, et al
   Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.
   J Immunol. 2024;212:1589-1601.
   

   >> Share

   
   January 2024
9. TOYOFUKU T, Ishikawa T, Nojima S, Kumanogoh A, et al
   Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.
   J Immunol. 2024 Jan 12:ji2300618. doi: 10.4049/jimmunol.2300618.
   

   >> Share

   
   October 2023
10. RAV E, Maegawa S, Gopalakrishnan V, Gordon N, et al
    Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma.
    J Immunol. 2023;211:1067-1072.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share